Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Official record

Identifier

NCT05998135

Recruiting locations

country

United States

Interventions studied

AtovaquoneBiopsyComputed TomographyParacentesis

Lead sponsor

Emory University

Target enrolment

28 participants

Study type

INTERVENTIONAL

Phase

Phase 2

Status

Recruiting

First posted

Aug 18, 2023

Last updated on the registry

Oct 1, 2026

Age

18 Years

Sex

FEMALE

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
* Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* There will be no limitations on number of prior lines of therapy
* Trial is open to non-English speaking patients
* Trial is open to patients referred from community practice

Exclusion Criteria:

* Patients who are \< 18 years old
* Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
* Patients who are incarcerated
* Patients who are unable to provide consent / lack decision-making capacity

Indexed under

Ovarian Cancer